Search Results
Dec 11, 2025, 17:31 ET Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as Johnson & Johnson, Arcellx, Gilead, Bristol Myers Squibb, Regeneron, AbbVie, CellCentric,
More news about: DelveInsight Business Research, LLP
Dec 11, 2025, 09:00 ET Insight Partners Appoints General Timothy Haugh, USAF (Ret.) and Former NSA Director, to Its Government Advisory Board
critical infrastructure, and deliver meaningful public outcomes.The GAB was founded with seven inaugural members, including the late Secretary Ash Carter, who served as the 25th United States Secretary of Defense. General Haugh's appointment completes this board of preeminent leaders
More news about: Insight Partners
Dec 11, 2025, 07:30 ET TuHURA Biosciences Provides Corporate Update Following Recent Financing
a menin inhibitor in NPM1 mutated relapsed/refractory AML Oral and poster presentations at the recently concluded 57th ASH Annual Meeting showed the Delta Opioid Receptor (DOR) to be a compelling new target as the cornerstone for the Company's bi-functional, bi-specific immune
More news about: TuHURA Biosciences, Inc.
Dec 10, 2025, 08:52 ET Dose-Intensive CK0804 Regimen Reduces Spleen Volume and Transfusion Needs in JAK Inhibitor-Resistant/ Suboptimal Myelofibrosis with Thrombocytopenia
in patients with myelofibrosis who had an inadequate response to standard-of-care therapy were presented at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida (
More news about: Cellenkos, Inc.
Dec 10, 2025, 07:29 ET China Premiere of 'Avatar: Fire and Ash' Highlight of 7th HIIFF
their creative experiences with industry professionals in masterclasses. Notably, the festival also hosted the China premiere of 'Avatar: Fire and Ash', with director James Cameron and several key members of the cast and crew making appearances that drew the rapt gaze of fans from around the world to
More news about: Hainan International Media Center (HIMC)
Dec 09, 2025, 11:57 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
present updated data from its BEACON Phase 1/2 clinical trial at the American Society of Hematology (ASH) Annual Meeting in December, advancing its base editing platform for sickle cell disease with severe vaso-occlusive crises. BEAM-101 represents a one-time,
More news about: Equity Insider
Dec 09, 2025, 09:30 ET 3iQ Appoints Ash Tahbazian as Head of Business Development, Canada
3iQ Corp. ("3iQ"), a global pioneer in digital asset investment solutions, today announced the appointment of Ash Tahbazian as Head of Business Development, Canada. In this role, Mr. Tahbazian will oversee national growth initiatives and expand 3iQ's presence among
More news about: 3iQ
Dec 09, 2025, 09:30 ET 3iQ Appoints Ash Tahbazian as Head of Business Development, Canada
3iQ Corp. ("3iQ"), a global pioneer in digital asset investment solutions, today announced the appointment of Ash Tahbazian as Head of Business Development, Canada. In this role, Mr. Tahbazian will oversee national growth initiatives and expand 3iQ's presence among
More news about: 3iQ
Dec 09, 2025, 08:00 ET Oral Presentation at ASH 2025 Shows Canopy RTM Cuts Infection-Related Hospitalizations by 52% and Generates Nearly $1M in Annual Savings per 1,000 Patients
Cannon Research Institute.The results from this study add to the growing body of evidence presented at ASH featuring the Canopy RTM Platform, including findings from the 2024 Annual ASH Meeting:37% reduction in treatment discontinuation at three months2
More news about: Canopy
Dec 09, 2025, 08:00 ET Curis Provides Updated Data from its Frontline AML Triplet Study
updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH).
More news about: Curis, Inc.
Dec 09, 2025, 08:00 ET Verismo Therapeutics Shares Positive Preclinical Data at ASH 2025 Comparing SynKIR™-310 With Conventional CAR T
KIR-CAR platform, today presented new preclinical data for SynKIR™-310, a CD19-targeting KIR-CAR T cell therapy, at the American Society of Hematology (ASH) Annual Meeting 2025. The presentation highlights key findings demonstrating that SynKIR™-310 achieved earlier tumor regression with deeper anti-tumor
More news about: Verismo Therapeutics
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
lines of therapy. The data were presented as a late-breaking oral presentation and in the press program at the 2025 American Society of Hematology (ASH) Annual Meeting, with simultaneous publication in
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Recordati Rare Diseases Announces Real-World Data on Long-Term Safety of ENJAYMO® (sutimlimab-jome) in Cold Agglutinin Disease and Cold Agglutinin Syndrome (CAD/CAS) at American Society of Hematology (ASH) Annual Meeting
therapy for hemolysis in adults with cold agglutinin disease (CAD). In a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla., researchers presented an updated analysis from the CADENCE registry1, the first multinational,
More news about: Raliance Communications
Dec 09, 2025, 07:30 ET Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL
untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
More news about: American Society of Hematology
Dec 09, 2025, 07:30 ET Drug Reduced Need for Blood Transfusions During Hospitalization for Non-Cardiac Surgery
potentially life-threatening blood clots (thrombosis) after 90 days of follow-up, according to research presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
More news about: American Society of Hematology
Dec 09, 2025, 07:30 ET Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
More news about: American Society of Hematology
Dec 09, 2025, 07:30 ET Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia
therapy. The study is the first to test a novel drug for ITP early in the disease course and was presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
More news about: American Society of Hematology
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
These data will be highlighted in a late-breaking oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida and simultaneously published in the Journal of Clinical Oncology."The results
More news about: Eli Lilly and Company
Dec 09, 2025, 07:00 ET HABANOS, S.A. PRESENTED PUNCH PRINCESAS: A NEW LIMITED EDITION CELEBRATING THE BRAND'S 185TH ANNIVERSARY
First third: The draw is correct and the burn is excellent, forming incandescent rings that progress evenly from the start, producing a compact ash that is light grey to grey in colour. On the palate, it offers a delicate and measured strength with subtle bitter nuances.Second
More news about: Habanos, S.A.
Dec 09, 2025, 07:00 ET HABANOS, S.A. PRESENTED PUNCH PRINCESAS: A NEW LIMITED EDITION CELEBRATING THE BRAND'S 185TH ANNIVERSARY
sheen.First third: The draw is correct and the burn is excellent, forming incandescent rings that progress evenly from the start, producing a compact ash that is light grey to grey in colour. On the palate, it offers a delicate and measured strength with subtle bitter nuances.Second third: The
More news about: Habanos, S.A.
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK
More news about: Dizal Pharmaceutical
Dec 08, 2025, 20:59 ET 【直擊2025 ASH】亞盛醫藥耐立克®治療TKI耐藥/不耐受CML-CP患者的註冊II期研究4年隨訪數據亮相，長期療效和安全性優勢再獲證實
More news about: 亞盛醫藥
Dec 08, 2025, 20:26 ET 【直擊2025 ASH】亞盛醫藥耐立克®治療初治Ph+ ALL患者註冊III期研究（POLARIS-1）數據國際首發， 最佳MRD陰性完全緩解率超60%
More news about: 亞盛醫藥
Dec 08, 2025, 14:45 ET Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study
The data, presented today in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, demonstrate clinically meaningful efficacy that was consistent across bleed locations, bleed types (spontaneous and traumatic),
More news about: Hemab Therapeutics